- Home
- ESEA vs HURA Comparison
ESEA vs HURA Comparison
Compare ESEA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESEA
- HURA
- Stock Information
- Founded
- ESEA 2005
- HURA 2009
- Country
- ESEA Greece
- HURA United States
- Employees
- ESEA N/A
- HURA N/A
- Industry
- ESEA Marine Transportation
- HURA
- Sector
- ESEA Consumer Discretionary
- HURA
- Exchange
- ESEA Nasdaq
- HURA Nasdaq
- Market Cap
- ESEA 208.2M
- HURA 171.7M
- IPO Year
- ESEA 2006
- HURA N/A
- Fundamental
- Price
- ESEA $44.94
- HURA $2.55
- Analyst Decision
- ESEA
- HURA Strong Buy
- Analyst Count
- ESEA 0
- HURA 2
- Target Price
- ESEA N/A
- HURA $11.50
- AVG Volume (30 Days)
- ESEA 29.6K
- HURA 128.8K
- Earning Date
- ESEA 06-18-2025
- HURA 08-15-2025
- Dividend Yield
- ESEA 5.80%
- HURA N/A
- EPS Growth
- ESEA 21.86
- HURA N/A
- EPS
- ESEA 18.62
- HURA N/A
- Revenue
- ESEA $222,525,034.00
- HURA N/A
- Revenue This Year
- ESEA $5.14
- HURA N/A
- Revenue Next Year
- ESEA $3.76
- HURA $69.15
- P/E Ratio
- ESEA $2.45
- HURA N/A
- Revenue Growth
- ESEA 14.62
- HURA N/A
- 52 Week Low
- ESEA $24.58
- HURA $1.80
- 52 Week High
- ESEA $50.82
- HURA $13.13
- Technical
- Relative Strength Index (RSI)
- ESEA 87.76
- HURA N/A
- Support Level
- ESEA $42.47
- HURA N/A
- Resistance Level
- ESEA $50.82
- HURA N/A
- Average True Range (ATR)
- ESEA 1.59
- HURA 0.00
- MACD
- ESEA 0.38
- HURA 0.00
- Stochastic Oscillator
- ESEA 66.24
- HURA 0.00
About ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.